What are the leading precision medicine concept stocks?
This is a well-deserved leading precision medicine stock, leading the vanguard of the industry. With cutting-edge technology and innovative thinking as its cornerstone, it continues to promote medical progress and human health. Its highly specialized team and advanced equipment to integrate medical changes into daily practice, the following Xiaobian brings what are the leading precision medicine concept stocks, I hope you like it.
What are the leading precision medicine concept stocks
1. Guilin Sankin (002275): The concept is the most authentic, especially with the U.S. stock market is currently the hottest celator with the most consistent "precision medicine + anti-cancer" concept. Its 100%-owned subsidiary, Baofeng Bio, has been working in the field of precision medicine for many years, and its core research and development personnel are Chinese Americans from large-scale well-known pharmaceutical companies. Baofeng Bio currently has two anti-cancer R&D programs, the Epiduo program (for the treatment of metastatic colorectal cancer) and the Herceptin program (mainly for the treatment of certain HER-2-positive breast cancers), both of which are best-selling anti-cancer drugs.
2. New open source (300109): the fixed-income acquisition of Sanji biological, Heer medical and Jingneng biological 100% equity. Acquisition of companies mainly do genetic testing.
3. Anke Bio (300009): in April 2016, the company intends to 449.88 million yuan to acquire 100% of the equity of Zhongde Meilian. The subject company's business scope includes bioengineering, biochips, genetically engineered antibodies and drugs, etc., belonging to the field of precision medicine.
4. Thousand Mountain Pharmaceutical Machinery (300216): Holding subsidiary Hong Hao gene individualized medication hypertension gene detection chip is currently growing faster.
What are the leading precision medicine stocks
1.Jingfeng medicine: leading pharmaceutical stocks.On December 21, 2018, the company announced that the company communicated with the U.S. FDA on the company's international multi-center phase III clinical trial of the anti-PD-1 antibody SHR-1210 combined with apatinib mesylate in the first-line treatment of hepatocellular carcinoma that the trial will soon be conducted simultaneously in the United States, Europe and China.
2, Haixiang Pharmaceuticals: leading pharmaceutical stocks. Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. is a listed company held by Guangzhou Pharmaceutical Group Co., Ltd. (A-share 600332, H-share 00874), mainly engaged in, (1) Chinese and Western patent medicines, chemical raw materials, natural medicines, biomedicine, chemical raw materials and pharmaceutical intermediates of research and development, manufacturing and sales; (2) Western medicine, Chinese medicine and medical equipment wholesale, retail and import and export business; (3) health products research and development, production and sales. Research and development, manufacture and sale of health products; and (4) investment in health industry such as medical services, health management and health care.
3, China Resources Sanjiu: pharmaceutical leading stocks. 2015 annual pharmaceutical industry profit is expected to 2,602 billion yuan, up 11,9%, the growth rate fell 0,4 percentage points.
4, Kunming Pharmaceutical Group: leading pharmaceutical stocks. The company plans to actively develop the e-commerce industry, expanding to the cell phone APP "State Drug Online", and adding "State Drug Online" channel, to increase the public attention of the State Drug Mall, to cope with the online sale of prescription drugs to loosen the binding, and begin to prepare for the BtoC model. Previously, the company's independently developed and independently operated B2B pharmaceutical e-commerce trading platform, Sinopharm Mall, was formally launched in October 2013, featuring product categories such as pharmaceuticals, food, oral supplies, birth control supplies, medical devices and cosmetics.
5, medicine stone science and technology: pharmaceutical leading stocks. Domestic pharmaceutical outsourcing industry leader, is the first to engage in pharmaceutical R & D production outsourcing CRO and CMO integration of the company, the senior management team *** has more than 200 authorized and applied for patent results; its main business for the discovery of small molecules of chemical drugs, R & D and production of a full range of integrated platform services, in the form of the whole industry chain platform for the global pharmaceutical companies to provide various types of new drug development, production and supporting services. The company also provides medical device testing and overseas precision medical R&D and production services.
What are the non-masked pharmaceutical stocks
1, Jianfan biological (300529): blood perfusion related products stock, China's blood perfusion field leading enterprises. Revenue and net profit for two consecutive years to maintain more than 32% growth, return on net assets of about 24%, gross profit margin of about 84%, dynamic price-earnings ratio of 46 times, the total market value of 24.3 billion.
2, myriad medical (300760): medical equipment leading stocks. Revenue and net profit continued high growth, return on net assets of 28% to 47%, gross profit margin of 66% dynamic price-earnings ratio of 44 times, total market capitalization of 177.1 billion. (Foreign to A-share listing)
3, Pharmacopeia (603259): CRO industry leading stock staring macro. Revenue and net profit continued high growth, return on net assets between 21 a 29%, gross profit margin of 39% or so, dynamic price-earnings ratio of 59 times, total market value of 92.7 billion. (Foreign to hole transport A shares listed)
4, Zhaoyan new drug (603127): 20% or so, gross profit margin of 53% or so pharmaceutical preclinical research service stocks, domestic industry leader in the field of security assessment. Revenue and net profit sustained high growth, return on net assets dynamic price-earnings ratio of 153 times, total market capitalization of 7.3 billion.
5, Aide Bio (300685): tumor precision medicine molecular diagnostics leading stocks. Revenue and net profit for three consecutive years to maintain more than 30% growth, return on net assets of about 20%, Mauna then beam rate of about 91%, dynamic price-earnings ratio of 59 times, total market capitalization of 7.7 billion.
6, OpusCare (300595): the domestic OK lens leading enterprises. Revenue and net profit for many years to maintain more than 30% growth, return on net assets between 21% and 38%, gross profit margin of 77% or so, the dynamic price-earnings ratio of 71 times, total market capitalization of 14.4 billion.
7, Dabo medical (002901): medical high health topic stocks, orthopedic implant class domestic leader. Revenue and net profit for three consecutive years to maintain more than 16% growth, return on net assets of more than 28%, gross profit margin of about 82%, dynamic price-earnings ratio of 40 times, total market capitalization of 13.4 billion.
8, Jianyou shares (603707): pharmaceutical raw materials, preparation stock, the domestic injection of time agent internationalization pioneer enterprises. Revenue and net profit for three consecutive years to maintain more than 32% growth, return on net assets of about 19%, gross profit margin of about 47%, dynamic price-earnings ratio of 31 times, total market capitalization of 19 billion.
9, Dazanlin (603233): South China's leading pharmaceutical chain. Revenue and net profit for two consecutive years to maintain double-digit growth, return on net assets of 18 a 37% of the dynamic price-earnings ratio of 31 times, total market value of 22.8 billion.
10, Kelaiying (002821): domestic COMO leading enterprises. Revenue and net profit
What are the top three stocks in terms of fundamentals
The top three stocks in terms of fundamentals are the following three.
1, Myriad Medical: domestic medical device leader. Mainly engaged in medical equipment research and development, manufacturing, marketing and service.
2, Hengrui Medicine: one of the strength of the domestic chemical pharmaceuticals, the most opportunity to challenge the international pharmaceutical giants of Chinese companies. Mainly engaged in drug research and development, production and sales.
3, WuXi AppTec: CRO + CDMO industry chain leader, the world's leading "integrated, end-to-end" new drug R & D service platform. Mainly engaged in the discovery of small molecule chemical drugs, R & D and production of a full range of integrated platform services, in the form of the whole industry chain platform for the global pharmaceutical companies to provide all kinds of new drug development, production and ancillary services, medical device testing and overseas precision medical R & D and production services.
Why Changhong Technology is a medical concept stock
The company is engaged in healthcare-related businesses. Shenzhen Changhong Mould Technology Co., Ltd. is a limited company registered on April 11, 2001 at the Shenzhen Industrial and Commercial Bureau. Based on the medical and healthcare industry and the precision mold and injection molding industry, Changhong Technology's main businesses include, OA, medical devices, precision medicine and assisted reproduction. The enterprise is a set of manufacturing, service as one of the professional precision mold manufacturing as well as injection molding product development and production enterprise group.